



Objectives

By the end of the presentation, the learner will have a clearer understanding of:

- ♦ The definition, prevalence, etiology and clinical features of pediatric gastroparesis.
- The management of pediatric gastroparesis.

Definition

Gastric motility disorder characterized by delayed gastric emptying (GE) in the absence of mechanical obstruction (liquid GE is often preserved)

Prevalence

- ♦ No data available on prevalence of gastroparesis in children
- \diamond M = F in 1 large retrospective study

What are the common causes of gastroparesis?

- ♦ Idiopathic 70%
- ♦ Drug-induced 18%
- ♦ Post-surgical 12.5%
- ♦ Post-viral 5%
- ♦ Diabetic 4%

- ♦ Idiopathic 70%
- ♦ Drug-induced 18%
- ♦ Post-surgical 12.5%
- ♦ Post-viral 5%
- ♦ Diabetic 4%

Common drugs causing gastroparesis:

Opioids, α-2 adrenergic agonists, TCA, anticholinergics, PPI, antacids, H2 receptor blockers, sucralfate, octreotide, β-adrenergic agonists, calcium channel blockers and diphenhydramine

- ♦ Idiopathic 70%
- ♦ Drug-induced 18%
- ♦ Post-surgical 12.5%
- ♦ Post-viral 5%
- ♦ Diabetic 4%

Common surgeries causing gastroparesis: Upper GI surgery and heart/lung transplantation

- ♦ Idiopathic 70%
- ♦ Drug-induced 18%
- ♦ Post-surgical 12.5%
- ♦ Post-viral 5%
- ♦ Diabetic 4%

Common viruses causing gastroparesis: Rotavirus, EBV and CMV

Usually self-limited and resolves within 24 months

Comorbidities

- ♦ Seizure disorders
- ♦ CP
- ♦ DD
- ♦ Prematurity
- * Behavioral problems such as ADHD, anxiety, and bipolar disorder

Comorbidities

GERD is a COMMON complication of gastroparesis.

Clinical Features

- ♦ Vomiting 68%
- ♦ Abdominal pain 51%
- ♦ Nausea 28%
- ♦ Weight loss 27%
- ♦ Early satiety 25%
- ♦ Postprandial fullness 7%

Correlation between the severity of symptoms and the degree of delayed GE is poorly defined.

Differential Diagnoses

- Esophagitis/gastritis
- ♦ Peptic ulcer disease
- ♦ SIBO
- ♦ Intestinal obstruction
- ♦ Functional dyspepsia
- Cyclical vomiting syndrome
- Rumination syndrome
- Medications (e.g., anti-neoplastic medications)

Investigations

Initial investigation: Upper gastrointestinal contrast study or upper GI scope to rule out mechanical obstruction

Investigations

Subsequent investigation: GE scintigraphy (gold standard) or breath test to confirm delayed GE

♦ Breath test's advantage is that it does not expose the patient to radiation, but it can be inaccurate in patients with specific conditions such as celiac disease and liver cirrhosis.

Investigations

Other methods that measure GE time: Transabdominal U/S, MRI and antroduodenal manometry

General:

- ♦ Treatment of underlying disease
- Correction of fluid and electrolyte imbalances
- ♦ Alleviation of symptoms
- ♦ Optimizing nutritional status
- ♦ Hospitalization for severe symptoms (e.g., intractable vomiting)

Diet and lifestyle changes:

- ♦ Small-volume and frequent meals with low content in fat and non-digestible fibers
- ♦ Avoidance of carbonated beverages and lying down for 1-2 h following meals
- ♦ Referral to a RD
- ♦ In severe/persistent cases:
 - Strict liquid diet
 - Enteral nutrition via naso-jejunal tube or jejunostomy
 - TPN if enteral nutrition fails

- > Prokinetics
- > Antiemetics
- > PPIs

- > Prokinetics
 - Metoclopramide: Dopamine antagonist, central antiemetic and peripheral prokinetic effects, side-effects (galactorrhea, extrapyramidal symptoms)

- > Prokinetics
 - Domperidone: Dopamine antagonist, peripheral prokinetic effect does not cross the BBB, side effects (galactorrhea, prolonged QTc)

- > Prokinetics
 - Erythromycin: Subtherapeutic dose (less than Abx dose) for its prokinetic agent, side-effects (pyloric stenosis in neonates, risk of prolonged QTc unclear)

- > Prokinetics
 - Cisapride: Serotonin 5-HT4 receptor agonist and parasympathomimetic, side-effect (prolonged QTc)

- > Prokinetics
 - Prucalopride: Serotonin 5-HT4 receptor agonist, side-effects (headache, GI symptoms such as abdominal pain, diarrhea, N/V)

- > Antiemetics:
 - Phenothiazines (e.g., prochlorperazine), 5-HT3 antagonists (e.g., ondasetron), dopamine antagonists (e.g., metoclopramide), histamine H1 antagonists (e.g., diphenydramine), and benzodiazepines (e.g., lorazepam)

- > PPIs:
 - Lansoprazole, omeprazole, esomeprazole, and pantoprazole to address associated GERD

Botox injections:

- ♦ Botulinum toxin type A
- Endoscopically injected into the pylorus
- ♦ Blocks the release of acetylcholine from cholinergic nerve endings → promotes GE
- Occasionally used in children with refractory gastroparesis

Gastric stimulator:

- ♦ Laparoscopic implantation of two electrodes into the seromuscular layer of the stomach → connected to a pacemaker
- Long-term efficacy and safety to be established

Surgery:

- ♦ Gastrostomy tube insertion:
 - To facilitate gastric ventilation and symptomatic relief
 - To place a jejunostomy tube for nutrition
- Reserved for refractory cases that fail medical treatment

Stepwise

approach in the diagnosis and treatment of gastroparesis

Baseline assessment of the patient

(detailed medical history, thorough physical examination)

♦ No identifiable cause of the symptoms

Exclusion of mechanical obstruction

(esophagogastroduodenoscopy, upper gastrointestinal barium series)

Assessement of gastric emptying time

(scintigraphy, breath testing)

Gastroparesis confirmed

Medical treatment

(dietary modifications, prokinetics, anti-emetics)

♦ Symptoms unremitting despite appropriate modification of the initial approach

Botulinum toxin injection or Surgical treatment

(jejunostomy, gastric electrical stimulator)

Total parenteral nutrition in the extreme case where all the above fail

References:

- ♦ Efstratios Saliakellis, Maria Fotoulaki; Gastroparesis in children, Annals of Gastroenterology (2013) 26, 204-211
- ♦ Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592-1622
- ♦ Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456-1462

Thank You!



ahmad.jaafar@medportal.ca